In the decade since oral rotavirus vaccines (ORV) were recommended by the World Health
Organization for universal inclusion in all national immunization programs, significant yet …

Introduction Rotavirus (RV) disease remains a prominent cause of disease burden in
children< 5 years of age worldwide. However, implementation of RV vaccination has led to …

Background A head-to-head comparison of the most widely used oral rotavirus vaccines has
not previously been done, particularly in a high child mortality setting. We therefore aimed to …

Background A randomized, double-blind, placebo-controlled multicenter trial was conducted
in healthy Chinese infants to assess the efficacy, immunogenicity and safety of a novel …

Group A rotaviruses (RVA) remain a leading cause of pediatric diarrhea worldwide, in part
due to underperformance of currently approved live-attenuated, oral vaccines in low-and …

Oral vaccines have several advantages compared with parenteral administration: they can
be relatively cheap to produce in high quantities, easier to administer, and induce intestinal …

The infant non-secretor histoblood group antigen phenotype is associated with reduced risk
of symptomatic rotavirus diarrhea, one of the leading global causes of severe pediatric …

The 2nd Next Generation Rotavirus Vaccine Developers Meeting, sponsored by PATH and
the Bill and Melinda Gates Foundation, was held in London, UK (7–8 June 2022), and …

Background Despite the availability and success of live-attenuated oral vaccines, rotavirus
(RV) remains the leading cause of pediatric gastroenteritis worldwide. Next-generation …